CYTK - Cytokinetics, Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
38.96
+0.33 (+0.85%)
As of 10:55AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close38.63
Open38.16
Bid38.79 x 1000
Ask38.88 x 2200
Day's Range38.16 - 38.99
52 Week Range32.96 - 55.80
Volume85,986
Avg. Volume958,246
Market Cap3.726B
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-4.77
Earnings DateAug 02, 2023 - Aug 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.93
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYTK

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    SOUTH SAN FRANCISCO, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2023 it granted stock options to purchase an aggregate of 76,800 shares of common stock to 7 new employees, whose employment commenced in May 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $37.69 per share, which is equal to the closing price of the Company’s common stock on May 31, 20

  • GlobeNewswire

    Cytokinetics to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: Jefferies Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Thursday, June 8, 2023 at 9:30 AM Eastern Time at the Marriott Marquis in New York, NY.Goldman

  • GlobeNewswire

    Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress

    Figure 2 REDWOOD-HCM Cohort 4: Angina Symptoms Figure 1 REDWOOD-HCM Cohort 4: Kansas City Cardiomyopathy Questionnaire (KCCQ) Figure 4 REDWOOD-HCM Cohort 4: Cardiac Biomarkers Figure 3 REDWOOD-HCM Cohort 4: New York Heart Association (NYHA) Functional Class Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H

  • GlobeNewswire

    Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress

    SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one Late Breaking Clinical Trial presentation and two moderated ePoster presentations at Heart Failure 2023 an International Congress of the European Society of Cardiology taking place online and in Prague, Czech Republic from May 20, 2023 – May 23, 2023. Late Breaking Clinical Trial Title: REDWOOD-HCM-Cohort 4: Aficamten in Non-Obstructive HCMPresenter: Ahmad Masri, M.D. M.S.,

  • GlobeNewswire

    Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586

    Advancement of Additional Cardiac Myosin Inhibitor Expands Specialty Cardiovascular PortfolioSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study of CK-4021586 (CK-586). CK-586 is a cardiac myosin inhibitor in development for the potential treatment of patients with h

  • GlobeNewswire

    Cytokinetics to Participate in the JMP Securities Life Sciences Conference

    SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:00 AM Eastern Time at the New York Hilton Midtown in New York, NY. Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics

  • Simply Wall St.

    Analysts' Revenue Estimates For Cytokinetics, Incorporated (NASDAQ:CYTK) Are Surging Higher

    Cytokinetics, Incorporated ( NASDAQ:CYTK ) shareholders will have a reason to smile today, with the analysts making...

  • Thomson Reuters StreetEvents

    Q1 2023 Cytokinetics Inc Earnings Call

    Q1 2023 Cytokinetics Inc Earnings Call

  • Zacks

    Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates

    Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cytokinetics Reports First Quarter 2023 Financial Results

    SEQUOIA-HCM Nearing Completion of Enrollment; On Track for Results in Q4 2023 Additional Data from Cohort 4 of REDWOOD-HCM to be Presented in Late-Breaking Clinical Trial Session at European Society of Cardiology Heart Failure 2023 Congress Company to Reduce Spending by More Than 10% in 2023 to Maintain Over 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2023. Net l

  • Simply Wall St.

    Shareholders Will Most Likely Find Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Acceptable

    Key Insights Cytokinetics to hold its Annual General Meeting on 10th of May Total pay for CEO Robert Blum includes...

  • GlobeNewswire

    Cytokinetics to Hold Annual Meeting of Stockholders

    SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 10, 2023 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance. St

  • Zacks

    Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline

    Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zacks

    Does Cytokinetics (CYTK) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?

    The consensus price target hints at a 62.8% upside potential for Cytokinetics (CYTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • Zacks

    Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Cytokinetics to Announce First Quarter Results on May 4, 2023

    SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the Invest

  • Simply Wall St.

    Estimating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)

    Key Insights The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity...

  • GlobeNewswire

    Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 10:00 AM Eastern Time. Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinet

  • Zacks

    Cytokinetics (CYTK) Dips 20% so Far in 2023 on Setbacks

    Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv mecarbil.

  • Benzinga

    Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility

    Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical trial. The DMC reviewed unblinded data from COURAGE-ALS and recommended discontinuing the clinical trial due to futility, as it found no evidence of effect in patients treated with reldesemtiv relative to placebo on the primary endpoint of change from baseline to 24 weeks in ALSFRS-R or in key seconda

  • American City Business Journals

    Peninsula drug maker Cytokinetics ends late-stage study in ALS

    Cytokinetics Inc. is discontinuing its late-stage study of a drug aimed at amyotrophic lateral sclerosis, the potentially deadly neuromuscular condition commonly known as Lou Gehrig's Disease. The South San Francisco company (NASDAQ: CYTK) said Friday a data monitoring committee recommended the Phase III clinical trial of the drug reldesemtiv be stopped after finding no evidence of effect in patients relative to placebo on improving a disease scale over 24 weeks. Cytokinetics' stock was up $1.09 per share, or more than 3%, to $35.30 in Friday morning trading.

  • GlobeNewswire

    Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis

    Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring Committee (DMC) for COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), rece

  • GlobeNewswire

    Cytokinetics Releases Inaugural Corporate Responsibility Report

    Report Highlights Company Commitment to Patient Centricity, Sustainability, Ethics, Diversity, Equity and InclusionSOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the release of its inaugural Corporate Responsibility Report, outlining the Company's commitment to social and environmental responsibility, ethics and governance and patient and community engagement. “At Cytokinetics, being a responsible corporate citizen is a n

  • Benzinga

    Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle

    Cytokinetics Incorporated (NASDAQ: CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). At ten weeks, patients in Cohort 4 experienced significant improvements in NT-proBNP, with an average decrease of 66%. High-sensitivity troponin I level also improved significantly proportional to baseline at each study visit. Related: FDA Rejects Cytokinetics' Heart Failure Treatment Candidate. An improvement of ≥

  • GlobeNewswire

    Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session

    Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement to Phase 3 Additional Results from FOREST-HCM Demonstrate Long-Term Treatment with Aficamten for 48 Weeks is Well-Tolerated and Associated with Sustained Treatment Effect Company to Host Investor Event and Conference Call on March 6, 2023 at 8:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif., March 04, 2023 (GLOBE NEWSWIRE) -- C